HIE represents the IND drug in the pipeline that can scale...

HIE represents the IND drug in the pipeline that can scale within NEU.... it does not involve a rare disease, but an acute brain injury in newborns, for which current solutions are limited and often inadequates.
If 2591 demonstrates efficacy in this context, it would prove that it can protect and promote the recovery of a distressed brain. Such evidences carries a value far greater than that of a single market.

This is why BigPh companies takes interest.… once a therapy is incorporated into Hospytal protocols, its adoption can spread quickly and stably, because it's not a “personal” choice but a practice shared at an institutional level.Because of the target populations is newborns, ABSOLUTE priority is safety and precise dose determination.... the organism in newborn is extremely vulnerable, with under developed organs, and it is essential to know EXACTLY how much active ingredients reaches the site of action and for how long it remains active.

So what...
For this reason, the FDA’s request for additional verification, although it lengthens development timelines, can be an advantage..... it forces the dossier to be solidified from the early stages, reducing the risk of unforeseen issues when the project is already advanced and requires substantial investment.
Thus, overall, this slowdown can INCREASE the product’s credibility: less “hope” and more RIGOR make it easier to persuade regulators, scientist physicians, and potential partners.If the results and data confirms the hypotheses, HIE will not only open a new commercial pathway but will also give rise to an entire FAMILY (read Platform) of future opportunities, since all areas related to hypoxic brain injury, both in children and ADULTS, will suddenly become explorable territories using the same what: PLATFORM.
Finger crossed.